These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10319212)

  • 21. The rationale of pharmacoeconomic analysis in rheumatologic indications.
    Turchetti G; Scalone L; Della Casa Alberighi O; Mosca M; Montella S; Cortesi PA; Mantovani LG
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S64-71. PubMed ID: 23072796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia.
    Wolfe F
    Rheumatology (Oxford); 1999 Apr; 38(4):355-61. PubMed ID: 10378714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis.
    Andrews G; Simonella L; Lapsley H; Sanderson K; March L
    J Rheumatol; 2006 Apr; 33(4):671-80. PubMed ID: 16541479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs and outcomes in rheumatoid arthritis and osteoarthritis.
    Liang MH; Larson M; Thompson M; Eaton H; McNamara E; Katz R; Taylor J
    Arthritis Rheum; 1984 May; 27(5):522-9. PubMed ID: 6721884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs.
    Lorig KR; Mazonson PD; Holman HR
    Arthritis Rheum; 1993 Apr; 36(4):439-46. PubMed ID: 8457219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
    Mora C; González A; Díaz J; Quintana G
    Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost of illness studies in rheumatic diseases.
    Fautrel B; Guillemin F
    Curr Opin Rheumatol; 2002 Mar; 14(2):121-6. PubMed ID: 11845016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis.
    Welsing PM; Severens JL; Hartman M; van Gestel AM; van Riel PL; Laan RF
    Pharmacoeconomics; 2006; 24(10):1011-20. PubMed ID: 17002483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls.
    Gabriel SE; Crowson CS; Campion ME; O'Fallon WM
    J Rheumatol; 1997 Jan; 24(1):43-8. PubMed ID: 9002009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The economic implications of cyclooxygenase-2-specific inhibitors.
    Peloso PM; Scheiman JM
    Am J Med; 2001 Feb; 110 Suppl 3A():50S-4S. PubMed ID: 11173051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pain conditions ranked by healthcare costs for members of a national health plan.
    Pasquale MK; Dufour R; Schaaf D; Reiners AT; Mardekian J; Joshi AV; Patel NC
    Pain Pract; 2014 Feb; 14(2):117-31. PubMed ID: 23601620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-life effectiveness of spa therapy in rheumatic and musculoskeletal diseases: a retrospective study of 819 patients.
    Karagülle M; Kardeş S; Karagülle MZ
    Int J Biometeorol; 2017 Nov; 61(11):1945-1956. PubMed ID: 28560466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substantial work disability and earnings losses in individuals less than age 65 with osteoarthritis: comparisons with rheumatoid arthritis.
    Pincus T; Mitchell JM; Burkhauser RV
    J Clin Epidemiol; 1989; 42(5):449-57. PubMed ID: 2732773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost assessment instrument in rheumatology: evaluation of applied instrument characteristics.
    Ruof J; Merkesdal S; Huelsemann JL; Schoeffski O; Maetzel A; Mau W; Zeidler H
    J Rheumatol; 2001 Mar; 28(3):662-5. PubMed ID: 11296978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
    Merkesdal S; Ruof J
    Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness and quality of life in knee arthroplasty.
    Lavernia CJ; Guzman JF; Gachupin-Garcia A
    Clin Orthop Relat Res; 1997 Dec; (345):134-9. PubMed ID: 9418630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis.
    Singh G; Miller JD; Huse DM; Pettitt D; D'Agostino RB; Russell MW
    J Rheumatol; 2003 Apr; 30(4):714-9. PubMed ID: 12672188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway.
    Svarvar P; Aly A
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():43-50. PubMed ID: 11276802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arthritis burden and impact are greater among U.S. women than men: intervention opportunities.
    Theis KA; Helmick CG; Hootman JM
    J Womens Health (Larchmt); 2007 May; 16(4):441-53. PubMed ID: 17521246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.